Potentiated Hsp104 Variants Antagonize Diverse Proteotoxic Misfolding Events  by Jackrel, Meredith E. et al.
Potentiated Hsp104 Variants
Antagonize Diverse Proteotoxic
Misfolding Events
Meredith E. Jackrel,1 Morgan E. DeSantis,1,2,5 Bryan A. Martinez,4 Laura M. Castellano,1,3 Rachel M. Stewart,1,6
Kim A. Caldwell,4 Guy A. Caldwell,4 and James Shorter1,2,3,*
1Department of Biochemistry and Biophysics
2Biochemistry and Molecular Biophysics Graduate Group
3Pharmacology Graduate Group
Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA
4Department of Biological Sciences, University of Alabama, Tuscaloosa, AL 35487, USA
5Present address: Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA
6Present address: Department of Cell Biology, Yale University School of Medicine, New Haven, CT 06520, USA
*Correspondence: jshorter@mail.med.upenn.edu
http://dx.doi.org/10.1016/j.cell.2013.11.047SUMMARY
There are no therapies that reverse the proteotoxic
misfolding events that underpin fatal neurodegener-
ative diseases, including amyotrophic lateral scle-
rosis (ALS) and Parkinson’s disease (PD). Hsp104,
a conserved hexameric AAA+ protein from yeast,
solubilizes disordered aggregates and amyloid but
has no metazoan homolog and only limited activity
against human neurodegenerative disease proteins.
Here, we reprogram Hsp104 to rescue TDP-43,
FUS, and a-synuclein proteotoxicity by mutating
single residues in helix 1, 2, or 3 of the middle domain
or the small domain of nucleotide-binding domain
1. Potentiated Hsp104 variants enhance aggregate
dissolution, restore proper protein localization, sup-
press proteotoxicity, and in a C. elegans PD model
attenuate dopaminergic neurodegeneration. Poten-
tiating mutations reconfigure how Hsp104 subunits
collaborate, desensitize Hsp104 to inhibition, obviate
any requirement for Hsp70, and enhance ATPase,
translocation, and unfoldase activity. Our work es-
tablishes that disease-associated aggregates and
amyloid are tractable targets and that enhanced dis-
aggregases can restore proteostasis and mitigate
neurodegeneration.INTRODUCTION
Protein misfolding underpins several fatal neurodegenerative
disorders, including amyotrophic lateral sclerosis (ALS) and Par-
kinson’s disease (PD) (Cushman et al., 2010). In PD, a-synuclein
(a-syn) forms highly toxic prefibrillar oligomers and amyloid fibrils
that accumulate in cytoplasmic Lewy bodies (Cushman et al.,170 Cell 156, 170–182, January 16, 2014 ª2014 Elsevier Inc.2010). In ALS, TDP-43 or FUS accumulate in cytoplasmic inclu-
sions in degenerating motor neurons (Robberecht and Philips,
2013). Unfortunately, treatments for these disorders are pallia-
tive and ineffective due to the apparent intractability of aggre-
gated proteins. Effective therapies are urgently needed that
eliminate the causative proteotoxic misfolded conformers via
degradation or reactivation of the proteins to their native fold.
Inspiration can be drawn from nature, where amyloidogene-
sis and protein misfolding have been subjugated for adaptive
modalities (Newby and Lindquist, 2013). For example, beneficial
yeast prions are tightly regulated by Hsp104, a hexameric AAA+
protein that rapidly deconstructs various amyloids andprefibrillar
oligomers (DeSantis et al., 2012; Lo Bianco et al., 2008; Newby
and Lindquist, 2013). Hsp104 also reactivates proteins from
disordered aggregates after environmental stress (Shorter,
2008). Hsp104 is highly conserved in eubacteria and eukaryotes,
except inmetazoa, which bafflingly lack anHsp104 homolog and
display limited ability to disaggregate disordered and amyloid
aggregates (Duennwald et al., 2012; Shorter, 2008, 2011).
Thus, Hsp104 could be harnessed to augment human proteosta-
sis and counter protein misfolding in neurodegenerative disease
(Shorter, 2008). Indeed, Hsp104 synergizes with human Hsp70
and Hsp40 to resolve various misfolded species linked with
human neurodegenerative disease and can partially antagonize
protein misfolding and neurodegeneration in metazoa (Cush-
man-Nick et al., 2013; DeSantis et al., 2012; Duennwald et al.,
2012; Lo Bianco et al., 2008; Shorter, 2011; Vacher et al.,
2005). Hsp70 overexpression can also mitigate neurodegen-
eration (Cushman-Nick et al., 2013). However, these potentially
therapeutic activities remain limited and vast improvements
are needed to maximize therapeutic potential. Indeed, very
high concentrations of Hsp104 are needed to antagonize
human neurodegenerative disease proteins, which Hsp104
never ordinarily encounters, and some substrates are refractory
to Hsp104 (DeSantis et al., 2012; Lo Bianco et al., 2008).
A key but elusive goal is to engineer or evolve optimized
chaperones against neurodegenerative disease substrates to
maximize therapeutic efficacy (Shorter, 2008). Chaperones are
impractical targets for protein engineering due to their typically
large size, and protein disaggregases such as Hsp104 have
poorly understood structures, making rational design chal-
lenging (Saibil, 2013). Here, we broach this issue and isolate
potentiated Hsp104 variants that eradicate TDP-43, FUS, and
a-syn aggregates and potently suppress toxicity. We report
several artificially engineered chaperones to optimize proteo-
stasis and thwart neurodegeneration.We suggest that neuropro-
tection may be possible for diverse neurodegenerative diseases
via subtle structural modifications of existing chaperones.
RESULTS
Substrate-Binding Tyrosines in Hsp104 Pore Loops Are
Optimal for Disaggregation
Hsp104 is adapted for disaggregation of the yeast proteome.
We sought to engineer Hsp104 variants to disaggregate TDP-
43, an RNA-binding protein with a prion-like domain (Cushman
et al., 2010), which has no yeast homolog and is not a natural
Hsp104 substrate. A yeast model of TDP-43 proteinopathies
has been developed in which TDP-43 is overexpressed via a
galactose-inducible promoter (Johnson et al., 2008). TDP-43
aggregates in the cytoplasm and is toxic to yeast, which pheno-
copies TDP-43 pathology in disease and has enabled identifica-
tion of common ALS genetic risk factors (Elden et al., 2010).
To explore Hsp104 sequence space against TDP-43 toxicity,
we employed Dhsp104 yeast to assess Hsp104 variants in the
absence of wild-type (WT) Hsp104. TDP-43 is highly toxic in
Dhsp104 yeast and Hsp104WT provides minimal rescue of
toxicity (Johnson et al., 2008). Thus, Dhsp104 yeast provide a
platform to isolate more active Hsp104 variants. Each Hsp104
monomer contains two nucleotide-binding domains (NBD1 and
NBD2) as well as an N-terminal, middle, and C-terminal domain
(DeSantis and Shorter, 2012). Hsp104 forms ring-shaped hex-
amers with a central pore through which substrate is threaded.
To alter substrate specificity, we assessed Hsp104 variants
bearing mutations in Hsp104’s two substrate-binding pore loops
(DeSantis and Shorter, 2012). We mutated the conserved pore
loop residues, Y257 and Y662, which mediate substrate binding
and translocation (Tessarz et al., 2008) to all amino acids and
screened this library of 400 variants for rescue of TDP-43
toxicity. After several rounds of selection, nearly all the variants
possessed Y at one or more often both pore-loop positions.
None of the pore-loop Hsp104 variants were more active than
Hsp104WT in rescuing TDP-43 toxicity. Thus, Y257 and Y662
are likely optimal for disaggregation.
Select Missense Mutations in the Middle Domain
Potentiate Hsp104 Activity
Next, we explored the coiled-coil middle domain (MD) of
Hsp104, which is less conserved than the substrate-binding
pore loops. MD variants can have unexpected gain-of-function
phenotypes (Schirmer et al., 2004). The Hsp104 MD (residues
411–538; Figure 1A) facilitates optimal ATPase activity, commu-
nication between NBD1 and NBD2, intrinsic disaggregase activ-
ity, and interactions with Hsp70 during disordered aggregate
dissolution (DeSantis and Shorter, 2012). We randomly muta-genized the MD and screened this Hsp104 library against
a-syn, FUS, or TDP-43 toxicity (Johnson et al., 2008; Outeiro
and Lindquist, 2003; Sun et al., 2011). We employed Dhsp104
yeast, as deletion of Hsp104 does not affect a-syn, FUS, or
TDP-43 toxicity (Johnson et al., 2008; Ju et al., 2011). We iden-
tified several Hsp104 variants that potently rescued a-syn,
FUS, and TDP-43 toxicity, whereas Hsp104WT was ineffective
(Figure 1B). Potentiated Hsp104 variants had a missense muta-
tion in helix 1 (Hsp104V426L) or in the distal loop between helix 1
and 2 (Hsp104A437W) or in helix 3 (Hsp104A503V or Hsp104Y507C)
(Figures 1A and 1B). Unexpectedly, we uncovered an enhanced
variant with a missense mutation in the NBD1 small domain
(Hsp104N539K) (Figures 1A and 1B). Thus, the MD or small
domain of NBD1 can be mutated to potentiate Hsp104 activity
against a-syn, FUS, and TDP-43.
Two potentiating mutations, A503V and Y507C, lie in MD helix
3. Thus, we performed a valine scan of helix 3 (residues 498–507)
in search of additional enhanced variants (Figures 1C and 1D).
Most helix-3 valine substitutions behaved like Hsp104WT
(Figure 1C). However, Hsp104D504V suppressed a-syn, FUS,
and TDP-43 toxicity (Figure 1C). Hsp104D498V and Hsp104Y507V
suppressed FUS and a-syn toxicity, but not TDP-43 toxicity (Fig-
ure 1C). Thus, select missense mutations in helix 3 engender
potentiated Hsp104 variants with altered substrate specificity.
TwodifferentY507mutations yieldedenhancedvariants. Thus,
we explored other substitutions at this position. Hsp104Y507A,
Hsp104Y507C, and Hsp104Y507D rescued a-syn, FUS, and TDP-
43 toxicity (Figure S1A available online). Likewise, additional sub-
stitutions at D504 (to C), V426 (to G), or N539 (to E, D, G, or K)
yielded potentiated Hsp104 variants against FUS toxicity (Fig-
ures S1A and S1B). Thus, diverse mutations at specific positions
in the MD enhance Hsp104 activity.
Hsp104A503X Variants Suppress TDP-43 Toxicity and
Promote Its Proper Localization
Hsp104A503V was among the strongest suppressors of a-syn,
FUS, and TDP-43 toxicity, and so we explored this position
further and mutated A503 to all amino acids. None of these
Hsp104 variants were toxic to yeast when overexpressed at
30C (Figure S2). Mutation of A503 to V, S, or C suppressed
TDP-43 toxicity; Hsp104A503C most strongly suppressed TDP-
43 toxicity, followed by Hsp104A503S and Hsp104A503V (Figures
2A, 2B, and S3A). Surprisingly, mutation of A503 to nearly any
residue suppressed TDP-43 toxicity, whereas Hsp104A503P
enhanced toxicity (Figures 2A and S3A). Indeed, we could now
mutate the conserved pore loop Y residues (Y257 and Y662) to
F (Hsp104A503V-DPLF) and retain suppression of TDP-43 toxicity
(Figure 2A). Rescue of TDP-43 toxicity was not due to lower
levels of TDP-43, which were roughly equal across strains (Fig-
ure 2C). Likewise, rescue could not be explained by higher
Hsp104 expression. Hsp104 variants were expressed at slightly
lower levels than Hsp104WT (Figure 2C). Quantitative immuno-
blot revealed that Hsp104 hexamer:TDP-43 ratios were
1:1.31 for Hsp104WT and 1:2.20 for Hsp104A503V. Hsp70
and Hsp26 levels were also similar for all strains, indicating
that Hsp104 variants do not induce a heat shock response
(HSR; Figure 2C). Hsp104A503V expression from the native
Hsp104 promoter (which is weaker than the galactose promoter)Cell 156, 170–182, January 16, 2014 ª2014 Elsevier Inc. 171
Figure 1. Hsp104 MD Variants Rescue Diverse Proteotoxicity Models
(A) Homology model of the MD and a portion of the small domain of NBD1 of Hsp104. Side chains of key residues are shown as sticks.
(B) Dhsp104 yeast strains integrated with galactose-inducible a-syn, FUS, or TDP-43 were transformed with the indicated Hsp104 variant or vector control.
Strains were serially diluted 5-fold and spotted on glucose (off) or galactose (on) media.
(C) Hsp104 variants harboring missense mutations to valine ranging from residue D498 to Y507 were expressed with a-syn, FUS, or TDP-43.
(D) Close-up of MD helix 3 from (A). Mutation of D498, A503, D504, or Y507 activates Hsp104.
See also Figure S1.suppressed TDP-43 toxicity (Figures S4A and S4B). Here, quan-
titative immunoblot revealed that Hsp104 hexamer:TDP-43 ra-
tios were 1:1.70 for Hsp104WT and 1:4.55 for Hsp104A503V.
Thus, even low Hsp104A503V levels rescued TDP-43 toxicity.
Finally, Hsp104A503V, Hsp104A503S, and Hsp104A503V-DPLF
rescued TDP-43 toxicity in Dire1 (to disrupt the unfolded protein
response [UPR]) and Datg8 (to disrupt autophagy) strains (Fig-
ure 2D). Thus, neither the UPR nor autophagy is needed for
enhanced Hsp104 variants to rescue TDP-43 toxicity.
TDP-43 normally shuttles between the nucleus and cyto-
plasm. However, in ALS, TDP-43 is usually depleted from the nu-172 Cell 156, 170–182, January 16, 2014 ª2014 Elsevier Inc.cleus and aggregated in the cytoplasm of degenerating motor
neurons (Robberecht and Philips, 2013). Indeed, cytoplasmic
TDP-43 aggregates persist uponHsp104WT overexpression (Fig-
ure 2E). By contrast, Hsp104A503V eliminated cytoplasmic
TDP-43 aggregates and 46% of cells had nuclear TDP-43
localization (Figure 2E). Accordingly, Hsp104A503V reduced the
amount of insoluble TDP-43 by 57%, whereas Hsp104WT
was ineffective (Figure 2F). Thus, Hsp104A503V eliminates TDP-
43 aggregation and toxicity and restores TDP-43 to the nucleus.
These phenotypes are a therapeutic goal for ALS and other TDP-
43 proteinopathies. Several suppressors of TDP-43 toxicity have
Figure 2. Hsp104A503X Variants Suppress TDP-43 Toxicity, Aggregation, and Mislocalization
(A)Dhsp104 yeast transformedwith TDP-43 andHsp104 variants, or YFP and vector, were serially diluted fivefold and spotted onto glucose (off) or galactose (on).
(B) Selected strains from (A) were induced in liquid and growth was monitored by A600nm.
(C) Strains from (B) were induced for 5 hr, lysed, and immunoblotted. Uninduced (untreated) and heat-shocked cells (HS) serve as controls. 3-Phosphoglycerate
kinase (PGK1) serves as a loading control.
(D) WT, Dire1, or Datg8 yeast were cotransformed with vector control or TDP-43 plus vector or the indicated Hsp104 variant and were serially diluted 5-fold and
spotted onto glucose (off) or galactose (on).
(E) Fluorescencemicroscopy of cells coexpressing fluorescently tagged TDP-43 andHsp104WT, Hsp104A503V, or vector. Cells were stained with DAPI to visualize
nuclei (blue). TDP-43 localization was quantified by counting the number of cells containing colocalized nuclear staining. Values represent means ± SEM (n = 3).
(F) Dhsp104 yeast cotransformed with TDP-43 and vector or the indicated Hsp104 variant were induced with galactose for 5 hr at 30C, lysed and processed for
sedimentation analysis and quantitative immunoblot. The relative amount of insoluble TDP-43 was determined as a percentage of the vector control. Values
represent means ± SEM (n = 2).
See also Figures S2, S3, and S4.been isolated in yeast, but none clear cytoplasmic TDP-43 ag-
gregates (Sun et al., 2011). Thus, our enhanced Hsp104 variants
are the first (to our knowledge) genetic suppressors that eradi-
cate TDP-43 aggregates and restore TDP-43 to the nucleus.
Hsp104A503X Variants Suppress FUS Toxicity and
Aggregation
Next, we tested Hsp104A503X variants for rescue of FUS toxicity
in yeast. FUS, like TDP-43, is a nuclear RNA-binding protein witha prion-like domain that forms cytoplasmic aggregates in degen-
erating neurons of FUS proteinopathy patients and in yeast (Ju
et al., 2011; Robberecht and Philips, 2013; Sun et al., 2011).
As for TDP-43, mutation of A503 to any amino acid except P
strongly suppressed FUS toxicity, as did Hsp104A503V-DPLF (Fig-
ures 3A, 3B, and S3B). Hsp104A503G most strongly suppressed
FUS toxicity (Figures 3A, 3B, and S3B). Rescue of FUS toxicity
by Hsp104A503X variants (or Hsp104D498V or Hsp104D504V) could
not be explained by lower FUS levels, induction of Hsp70 orCell 156, 170–182, January 16, 2014 ª2014 Elsevier Inc. 173
Figure 3. Hsp104A503X Variants Suppress FUS Toxicity and Aggregation
(A) Dhsp104 yeast transformed with FUS and the Hsp104 variants, or YFP and vector, were serially diluted 5-fold and spotted onto glucose (off) or galactose (on).
(B) Selected strains from (A) were induced in liquid and growth was monitored by A600nm.
(C) Strains from (B) were induced for 5 hr, lysed, and immunoblotted.
(D) WT, Dire1, or Datg8 yeast were cotransformed with vector control, or FUS plus vector, or the indicated Hsp104 variant and were serially diluted 5-fold and
spotted onto glucose (off) or galactose (on).
(E) Fluorescence microscopy of cells coexpressing FUS-GFP and Hsp104WT, Hsp104A503V, or vector. Cells were stained with Hoechst dye to visualize nuclei
(blue). FUS aggregation was quantified by counting the number of cells containing 0, 1, or more than 1 foci. Values represent means ± SEM (n = 3).
(F) Dhsp104 yeast cotransformed with FUS and vector or the indicated Hsp104 variant were induced with galactose for 5 hr at 30C, lysed, and processed for
sedimentation analysis and quantitative immunoblot. The relative amount of insoluble FUS was determined as a percentage of the vector control. Values
represent means ± SEM (n = 2).
See also Figures S3 and S4.Hsp26 in a HSR, or higher Hsp104 levels (Figure 3C). Indeed,
quantitative immunoblot revealed that Hsp104 hexamer:FUS ra-
tios were 1:5.13 for Hsp104WT and 1:3.25 for Hsp104A503V.
Even low Hsp104A503V levels expressed from the natural
Hsp104 promoter suppressed FUS toxicity (Figures S4C and
S4D). Here, quantitative immunoblot revealed that Hsp104
hexamer:FUS ratios were 1:5.21 for Hsp104WT and 1:9.58174 Cell 156, 170–182, January 16, 2014 ª2014 Elsevier Inc.for Hsp104A503V. Rescue of FUS toxicity by Hsp104A503V,
Hsp104A503S, and Hsp104A503V-DPLF occurred in Dire1 strains
and Datg8 strains (Figure 3D). Thus, the UPR and autophagy
are not required for potentiated Hsp104 variants to suppress
FUS toxicity.
Hsp104A503V eliminated FUS aggregates, whereas Hsp104WT
had no effect (Figure 3E). In contrast to TDP-43, FUS was now
diffuse in the cytoplasm (Figure 3E) because the yeast nuclear
transport machinery fails to decode the FUS PY-NLS (Ju
et al., 2011). Hsp104A503V reduced the amount of insoluble
FUS by 49%, whereas Hsp104WT was ineffective (Figure 3F).
Genome-wide overexpression screens have yielded several
suppressors of FUS toxicity in yeast, but none that solubilize
FUS inclusions (Ju et al., 2011; Sun et al., 2011). Thus, potenti-
ated Hsp104 variants are the first (to our knowledge) genetic
suppressors that eradicate FUS aggregates.
Hsp104A503X Variants Suppress a-Syn Toxicity and
Promote Its Proper Localization
Next, we tested Hsp104A503X variants against a-syn toxicity in
yeast. a-Syn is a lipid-binding protein that localizes to the plasma
membrane but forms cytoplasmic inclusions in degenerating
dopaminergic neurons in PD and in yeast (Cushman et al., 2010;
Outeiro andLindquist, 2003). Nearly all Hsp104A503X variants sup-
pressed a-syn toxicity except Hsp104A503P, which had no effect
(Figures 4A, 4B, and S3C). By contrast, Hsp104WT slightly
enhanced a-syn toxicity (Figures 4A and 4B). Hsp104A503V-DPLF
suppresseda-syn toxicity, thoughnot as strongly asHsp104A503V
(Figure 4A). Rescue of a-syn toxicity by Hsp104A503X variants
(or Hsp104D504V) could not be explained by lower a-syn levels,
induction of Hsp70 or Hsp26 in a HSR, or higher Hsp104 levels
(Figure 4C). Quantitative immunoblot indicated that the Hsp104
hexamer:a-syn ratios were 1:2.43 for Hsp104WT and 1:2.84
for Hsp104A503V. Expression of Hsp104A503V from the Hsp104
promoter suppressed a-syn toxicity, whereas Hsp104WT had no
effect (Figures S4E and S4F). Here, quantitative immunoblot
indicated that the Hsp104 hexamer:a-syn ratios were 1:3.03
for Hsp104WT and 1:5.79 for Hsp104A503V. Hsp104A503V,
Hsp104A503S, and Hsp104A503V-DPLF rescued a-syn toxicity in
Dire1andDatg8 strains (Figure 4D). Thus, theUPRandautophagy
are not required for rescue.
Hsp104A503V eliminated cytoplasmic a-syn inclusions and
restored plasma membrane a-syn localization, whereas
Hsp104WT had no effect (Figure 4E). Indeed, Hsp104A503V
reduced the amount of insoluble a-syn by 66%, whereas
Hsp104WT increased it by33.9% (Figure 4F). Thus, potentiated
Hsp104 variants eradicate a-syn inclusions and restore a-syn
localization.
Potentiated Hsp104 Variants Prevent
Neurodegeneration in a C. elegans PD Model
To test potentiated Hsp104 variants in a metazoan nervous
system, we used a transgenic C. elegans PD model, which has
illuminated mechanisms and modifiers of a-syn-induced neuro-
degeneration (Cao et al., 2005; Cooper et al., 2006; Tardiff et al.,
2013). We selected Hsp104A503S and Hsp104A503V-DPLF to study
in this context, which displayed strong (Hsp104A503S) and
moderate (Hsp104A503V-DPLF) rescue of a-syn toxicity (Figure 4A).
We focused on these variants because unlike Hsp104A503V they
conferred greater than WT levels of thermotolerance and were
less toxic to yeast at 37C when expressed from the galactose
promoter (Figures S5A and S5B).
The dopamine transporter (dat-1) gene promoter was used to
direct expression of Hsp104 variants and a-syn to dopaminergic
(DA) neurons. Expression of a-syn alone resulted in 16% ofanimals with normal numbers of DA neurons after 7 days
and 8% of animals after 10 days compared to controls
(Figures 5A–5C). Coexpression of Hsp104WT or an ATPase-
dead, substrate binding-deficient Hsp104DPLA-DWB (which bears
the ‘‘double pore loop’’ and ‘‘double Walker B’’ mutations:
Y257A:E285Q:Y662A:E687Q) did not rescue neurodegeneration
(Figures 5A and 5B). C. elegans expressing Hsp104A503S or
Hsp104A503V-DPLF displayed significant protection (30.5% and
34% normal worms, respectively) compared to the null Hsp104
variant or a-syn alone at day 7 (Figure 5A). This trend continued
at day 10 (Figure 5B), when Hsp104A503S-expressing (21%)
and Hsp104A503V-DPLF-expressing (24%) worms had signifi-
cantly more normal DA neurons compared to a-syn alone
(7.8%), Hsp104DPLA-DWB (10%), or Hsp104WT (11%). Hsp104
variants did not alter a-syn mRNA levels (Figure S5C). Thus,
Hsp104A503S and Hsp104A503V-DPLF remain significantly neuro-
protective against a-syn toxicity even as animals age.
Potentiated Hsp104 Variants Typically Have Elevated
ATPase Activity
Nearly all of the Hsp104A503X variants suppressed a-syn, FUS,
and TDP-43 toxicity in yeast. This unexpected degeneracy is
intriguing as there are few, if any, examples of missense muta-
tions to nearly any class of residue that lead to a therapeutic
gain of function. To explore the mechanism behind this gain of
function, we assessed the biochemical properties of several
Hsp104 variants that suppressed toxicity. Each Hsp104A503X
variant and Hsp104Y507C exhibited 2- to 4-fold higher ATPase
activity than Hsp104WT (Figure 6A). Hsp104D498V has higher
ATPase activity than Hsp104WT, though not as high as the
Hsp104A503X variants (Figure 6A). Hsp104D504C had ATPase ac-
tivity similar to Hsp104WT (Figure 6A). Thus, enhanced Hsp104
variants typically have higher ATPase activity than Hsp104WT.
However, Hsp104D504C illustrates that elevated ATPase activity
is not absolutely required for potentiation.
Potentiated Hsp104 Variants Do Not Require Hsp70 and
Hsp40 for Disaggregation
Rescue of toxicity by enhanced Hsp104 variants might reflect an
altered mechanism of disaggregation. Thus, we assessed activ-
ity against disordered luciferase aggregates (DeSantis et al.,
2012). Hsp104WT was inactive alone and required Hsp70 and
Hsp40, which could be from human (Hsc70 and Hdj2) or yeast
(Ssa1 and Ydj1; Figures 6B and 6C). By contrast, potentiated
Hsp104 variants were extremely active without Hsp70 and
Hsp40, and with the exception of Hsp104D504C, Hsc70 and
Hdj2 further increased activity (Figures 6B and 6C). Typically,
in the absence of Hsc70 and Hdj2, potentiated Hsp104 variants
were 3- to 9-fold more active than Hsp104WT plus Hsc70
and Hdj2 (Figure 6B). The only exception was Hsp104D498V,
which in the absence of Hsc70 and Hdj2 was still as active
as Hsp104WT plus Hsc70 and Hdj2 (Figure 6B). Hsp104WT was
most active in the presence of Ssa1, Ydj1, and the Hsp110,
Sse1 (Figure 6C) (Shorter, 2011). However, even here, Hsp104WT
luciferase reactivation activity only reached Hsp104A503V,
Hsp104A503S, and Hsp104A503V-DPLF activity in the absence
of Ssa1, Ydj1, and Sse1 (Figure 6C). In the presence of
Ssa1, Ydj1, and Sse1, the luciferase reactivation activity ofCell 156, 170–182, January 16, 2014 ª2014 Elsevier Inc. 175
Figure 4. Hsp104A503X Variants Suppress a-Syn Toxicity, Aggregation, and Mislocalization
(A)Dhsp104 yeast cotransformedwith two copies of a-syn-YFP and the Hsp104 variants, or YFP and vector, were serially diluted 5-fold and spotted onto glucose
(off) or galactose (on).
(B) Selected strains from (A) were induced in liquid and growth was monitored by A600nm.
(C) Strains from (B) were induced for 8 hr in galactose, lysed, and immunoblotted.
(D) WT, Dire1, or Datg8 yeast were cotransformed with vector controls or a-syn plus vector or the indicated Hsp104 variant and were serially diluted 5-fold and
spotted onto glucose (off) or galactose (on).
(E) Fluorescence microscopy of cells coexpressing a-syn-YFP and Hsp104WT, Hsp104A503V, or vector. a-Syn localization was quantified by counting the number
of cells with plasma membrane fluorescence or cytoplasmic aggregates. Values represent means ± SEM (n = 3).
(F) Dhsp104 yeast cotransformed with a-syn and vector or the indicated Hsp104 variant were induced with galactose for 8 hr at 30C, lysed, and processed for
sedimentation analysis and quantitative immunoblot. The relative amount of insoluble a-syn was determined as a percentage of the vector control. Values
represent means ± SEM (n = 2).
See also Figures S3 and S4.Hsp104A503V, Hsp104A503S, and Hsp104A503V-DPLF was 7- to
8-fold higher than Hsp104WT (Figure 6C). Potentiated Hsp104
variants are highly active without Hsp70 and Hsp40 (Figures
6B and 6C). Thus, absolute dependence on Hsp70 and Hsp40
hinders Hsp104 from rescuing a-syn, FUS, and TDP-43 toxicity.176 Cell 156, 170–182, January 16, 2014 ª2014 Elsevier Inc.Independence from Hsp70 and Hsp40 is promising for applying
Hsp104 variants to reverse protein misfolding in diverse sys-
tems, such as purification of aggregation-prone recombinant
proteins from E. coli where DnaK incompatibility is an issue
(DeSantis and Shorter, 2012).
Figure 5. Hsp104A503S and Hsp104A503V-DPLF
Protect Against a-Syn Toxicity and Dopami-
nergic Neurodegeneration in C. elegans
(A) Hsp104 variants and a-syn were coexpressed in
the dopaminergic (DA) neurons of C. elegans. Her-
maphrodite nematodes have six anterior DA neu-
rons, which were scored at day 7 posthatching.
Hsp104A503S and Hsp104A503V-DPLF have signifi-
cantly greater protective activity than both a-syn
alone and the null variant. Normal worms have a full
complement of DA neurons at this time.
(B) At day 10, there is a decline in wormswith normal
DA neurons. Hsp104A503S and Hsp104A503V-DPLF
exhibit greater protective activity when compared
to Hsp104WT and the null variant. Values represent
means ± SEM (of three independent experiments,
n = 30 per replicate with three to four replicates per
independent experiment; *p < 0.05, one-way
ANOVA group). Normal worms have a full comple-
ment of DA neurons at this time.
(C) Photomicrographs of the anterior region of
C. elegans coexpressing GFP with a-syn. Worms
expressing a-syn alone (left) exhibit an age depen-
dent loss of DA neurons. Worms expressing a-syn
plus Hsp104A503S (right) exhibit greater neuronal
integrity. Arrows indicate degenerating or missing
neurons. Triangles indicate normal neurons.
See also Figure S5.Potentiated Hsp104 Variants Translocate Substrate
Faster Than Hsp104WT
We next determined that potentiated Hsp104 variants displayed
accelerated substrate translocation. Thus, we used an Hsp104
variant, termed HAP, where G739-K741 are mutated to IGF,
which enables association with the chambered peptidase ClpP
(Tessarz et al., 2008). In the presence of ClpP, translocated sub-
strates are degraded rather than released. Thus, HAP translo-
cates fluorescein isothiocyanate (FITC)-casein for degradation
by ClpP, thereby releasing FITC and increasing fluorescence. In
the presence of ClpP, HAPA503V (Km1.29mM) is amore effective
FITC-casein translocase than HAPWT (Km 2.88mM) (Figure 6D).
The lower Km for HAP
A503V might reflect differences in substrate
recognition rather than translocation speed. However, the Kd
of Hsp104WT (Kd 65 nM) and Hsp104A503V (Kd 80 nM) for
FITC-casein were similar (Figure 6E) as were binding kinetics
(Figure 6F). Thus, substrate recognition by Hsp104WT and
Hsp104A503V is very similar. Hence, we suggest that Hsp104A503V
translocates substratemore rapidly thanHsp104WT. Accelerated
translocation likely enables potentiated variants to avoid kinetic
traps and exert additional force to unfold stable substrates.
Potentiated Hsp104 Variants Are Enhanced Unfoldases
Next, we established that enhanced Hsp104 variants had
enhanced unfoldase activity using a RepA1-70-GFP substrate
(Doyle et al., 2007). To assess RepA1-70-GFP unfolding in the
absence of spontaneous refolding, we added GroELtrap, which
captures unfolded proteins and prevents refolding (Weber-Ban
et al., 1999). Hsp104WT unfolds RepA1-70-GFP, but only in the
presence of a permissive ratio of ATP and ATPgS (Doyle
et al., 2007) (Figures 6G and 6H). Thus, with ATP alone,
Hsp104WT did not unfold RepA1-70-GFP (Figure 6G). By contrast,Hsp104A503X variants rapidly unfoldedRepA1-70-GFP in the pres-
ence of ATP (Figure 6G). Hsp104WT unfolded RepA1-70-GFP in
the presence of an ATP:ATPgS (3:1) mixture. By contrast, ATP:
ATPgS slightly inhibited Hsp104A503V unfoldase activity, but
even here, Hsp104A503V unfolded RepA1-70-GFP more rapidly
than Hsp104WT (Figure 6G). Hsp104A503X variants had very
similar unfoldase kinetics (Figure 6G). By contrast, Hsp104D498V,
Hsp104D504C, and Hsp104A503V-DPLF were slightly slower unfol-
dases than Hsp104A503V, whereas Hsp104Y507C was slightly
faster (Figure 6H). These differences could reflect changes in
substrate recognition or turnover or both. Regardless, potenti-
ated Hsp104 variants are enhanced unfoldases that are intrinsi-
cally primed to unfold substrates and do not have to wait for
regulatory events (mimicked here by ATPgS addition).
Hsp104A503V Hexamers Are Tuned Differently Than
Hsp104WT Hexamers
Do potentiated Hsp104 variants employ the same mechanism of
intersubunit collaboration as Hsp104WT to disaggregate pro-
teins? How Hsp104 subunits within the hexamer collaborate to
promote disaggregation can be interrogated via mutant subunit
doping. Here, mutant subunits defective in ATP hydrolysis, sub-
strate binding, or both are mixed with WT subunits to generate
heterohexamer ensembles according to the binomial distribution
(DeSantis et al., 2012). Hsp104 forms dynamic hexamers that
exchange subunits on the minute timescale, which ensures sta-
tistical incorporation of mutant subunits (DeSantis et al., 2012).
The disaggregase activity of various heterohexamer ensembles
enables determination of the number of mutant subunits that
inactivate the WT hexamer. Thus, we can determine if subunit
collaborationwithinHsp104 hexamers is probabilistic (sixmutant
subunits are required to abolish activity), subglobally cooperativeCell 156, 170–182, January 16, 2014 ª2014 Elsevier Inc. 177
Figure 6. Potentiated Hsp104 Variants Are Tuned Differently Than Hsp104WT
(A) ATPase activity of Hsp104 variants. Values represent means ± SEM (n = 3).
(B) Luciferase aggregates were incubated with Hsp104 variant plus (checkered bars) or minus (clear bars) Hsc70 (0.167 mM) and Hdj2 (0.167 mM). Values
represent means ± SEM (n = 3).
(C) Luciferase aggregates were incubated with Hsp104 variant plus or minus Hsc70 (0.167 mM) and Hdj2 (0.073 mM); Ssa1 and Ydj1; or Ssa1, Ydj1, and Sse1.
Values represent means ± SEM (n = 3).
(D) Increasing concentrations of FITC-casein were incubated with ClpP plus HAPWT or HAPA503V. Initial degradation rates were plotted against FITC-casein
concentration to determine Km. Values represent means ± SEM (n = 3).
(E) FITC-casein was incubated with increasing concentrations of Hsp104WT or Hsp104A503V. Change in fluorescence polarization was plotted against Hsp104
concentration to determine Kd. Values represent means ± SEM (n = 3).
(F)Kinetics ofHsp104WT (1mM)orHsp104A503V (1mM)binding toFITC-casein (0.1mM)assessedbyfluorescencepolarization. Values representmeans±SEM(n=3).
(G and H) RepA1-70-GFP was incubated with Hsp104 variant and GroEL
trap plus ATP or ATP:ATPgS (3:1). GFP unfolding was measured by fluorescence.
Representative data are shown.
(I) Buffer, Hsp104A503V-DWA, or Hsp104A503V-DPLA was mixed in varying ratios with Hsp104A503V to create heterohexamer ensembles and luciferase disaggregase
activity was assessed. Values represent means ± SEM (n = 3). Black line denotes the theoretical curve of a probabilistic mechanism where only a single A503V
subunit is required for disaggregation.
(J) Experiments were performed as in (I) for Hsp104A503V-DWB andHsp104A503V-DPLA-DWB. Theoretical curves are shownwherein adjacent pairs of A503V:A503V or
A503V:mutant subunits confer hexamer activity, while adjacent mutant subunits have no activity. Each adjacent A503V:A503V pair has an activity of 1/6. Adjacent
A503V:mutant pairs have a stimulated activity (s), and the effect of various s values are depicted. Values represent means ± SEM (n = 3).(two to five mutant subunits abolish activity), or globally cooper-
ative (one mutant subunit abolishes activity) (DeSantis et al.,
2012). Incorporation of Hsp104A503V-DWA subunits (which bear
the ‘‘double Walker A’’ [DWA] K218T:K620T mutations and
cannot bind ATP) or Hsp104A503V-DPLA subunits (which bear the
‘‘double pore loop’’ [DPL] Y257A:Y662A mutations and cannot
bind substrate) into Hsp104A503V hexamers caused a roughly
linear decline in luciferase disaggregase activity (Figure 6I). This
linear decline indicates that, likeHsp104WT,Hsp104A503V hexam-
ers resolve disordered aggregates via a probabilistic mechanism
(DeSantis et al., 2012). Thus, a single Hsp104A503V subunit per
hexamer able to hydrolyze ATP and engage substrate can drive
disaggregation.178 Cell 156, 170–182, January 16, 2014 ª2014 Elsevier Inc.However, Hsp104A503V hexamers operate differently than
Hsp104WT hexamers. A single Hsp104DWB subunit (which bears
the ‘‘double Walker B’’ [DWB] E285Q:E687Q mutations and can
bind but not hydrolyze ATP) inactivates the Hsp104WT hexamer
(DeSantis et al., 2012). By contrast, the luciferase disaggregase
activity of Hsp104A503V was stimulated by Hsp104A503V-DWB sub-
units (Figure 6J). Fluorescence resonance energy transfer (FRET)
studies confirmed that Hsp104A503V-DWB subunits incorporated
into Hsp104A503V hexamers. The FRET efficiency was 0.36
(compared to 0.38 for mixing Hsp104WT with Hsp104DWB;
DeSantis et al., 2012) using the conditions employed for lucif-
erase reactivation. In high-salt buffer (1 M NaCl), hexamerization
is inhibited and FRET efficiency decreased to 0.24. At a higher
Hsp104concentration (1mM),which favors hexamerization, FRET
efficiency increased to 0.43. We could model the stimulatory ef-
fect of Hsp104A503V-DWB subunits if we imposed rules whereby
an Hsp104A503V-DWB subunit stimulates activity of an adjacent
Hsp104A503V subunit 2-fold (Figure 6J). This stimulation
depended on substrate binding by Hsp104A503V-DWB as
Hsp104A503V-DPLA-DWB subunits (which bear the ‘‘double pore
loop’’ and DWB Y257A:E285Q:Y662A:E687Q mutations and
canbind, but not hydrolyze, ATPandcannot bindsubstrate) failed
to stimulate adjacent Hsp104A503V subunits (Figure 6J). Thus,
Hsp104A503V hexamers operate via principles distinct from those
of Hsp104WT hexamers. The Hsp104A503V hexamer displays
greaterplasticityand toleratesawider varietyof subunit-inactivat-
ing events to maintain a robust disaggregase activity. Thus, an
Hsp104A503V subunit that (1) binds but cannot hydrolyze ATP
and (2) engages substrate stimulates the disaggregase activity
of anadjacentHsp104A503V subunit. InHsp104WT, a singlesubunit
with these properties inactivates the hexamer. The increased re-
silience of Hsp104A503V hexamers to subunit-inactivating events
likely empowers facile resolution of recalcitrant substrates.
Hsp104A503V, Hsp104A503S, and Hsp104A503V-DPLF
Disaggregate Preformed a-Syn Fibrils More
Efficaciously Than Hsp104WT
To test Hsp104A503V, Hsp104A503S, and Hsp104A503V-DPLF in
comparison to Hsp104WT against a recalcitrant PD-associated
substrate we employed a-syn fibrils, allowing us to distinguish
if Hsp104 prevented amyloid formation or eliminated preformed
amyloid. Hsp104A503V, Hsp104A503S, and Hsp104A503V-DPLF dis-
aggregated preformed a-syn fibrils at concentrations where
Hsp104WT was inactive (Figures 7A–7C). Indeed, electron micro-
scopy (EM) revealed that a-syn fibrils were converted to small
structures by low concentrations of Hsp104A503V, Hsp104A503S,
and Hsp104A503V-DPLF, whereas Hsp104WT left fibrils intact (Fig-
ure 7C). Thus, Hsp104A503V, Hsp104A503S, andHsp104A503V-DPLF
are more powerful amyloid disaggregases than Hsp104WT.
Hsp104A503V and Hsp104A503S Disaggregate Preformed
TDP-43 and FUS Aggregates More Efficaciously Than
Hsp104WT
Next, we tested whether Hsp104A503V and Hsp104A503S were
more potent disaggregases of TDP-43 and FUS (Johnson
et al., 2009; Sun et al., 2011). Hsp104WT was unable to resolve
TDP-43 aggregates and slightly enhanced TDP-43 aggregation
in the absence of Ssa1, Ydj1, and Sse1 (Figure 7D). By contrast,
Hsp104A503V and Hsp104A503S partially resolved TDP-43 aggre-
gates in the absence of Ssa1, Ydj1, and Sse1 (Figure 7D).
Hsp104A503V and Hsp104A503S in the presence of Ssa1, Ydj1,
and Sse1, but not Hsp104WT, effectively dissolved short TDP-
43 filaments and amorphous structures (Figures 7D and 7E).
Very similar results were obtained with preformed FUS fibrils
(Figures 7F and 7G). Hsp104WT slightly increased FUS aggrega-
tion in the absence of Ssa1, Ydj1, and Sse1, whereas
Hsp104A503V and Hsp104A503S modestly reduced aggregation
(Figure 7F). Hsp104A503V and Hsp104A503S effectively disaggre-
gated FUS in the presence of Ssa1, Ydj1, and Sse1, whereas
Hsp104WT was ineffective (Figure 7F). Indeed, Hsp104A503V
and Hsp104A503S eradicated FUS fibrils (Figure 7G). Thus,Hsp104A503V and Hsp104A503S disaggregate preformed TDP-
43 and FUS aggregates more efficaciously than Hsp104WT.
DISCUSSION
Here, we demonstrate that Hsp104, a protein disaggregase from
yeast, can be modified to powerfully eradicate diverse sub-
strates implicated in ALS and PD. We have developed the first
(to our knowledge) disaggregases (or even chaperones) engi-
neered to optimize proteostasis. Indeed, enhanced Hsp104
variants are the first agents defined to reverse TDP-43 and
FUS aggregation. They not only suppress toxicity and eliminate
protein aggregates but also restore proper protein localization.
Importantly, these Hsp104 variants are not overtly toxic like other
MD mutants (Lipinska et al., 2013). Thus, potentiated Hsp104
variants can be uncovered that are not invariably toxic and that
rescue various toxic neurodegenerative disease proteins
in vitro and in vivo under conditions where Hsp104WT is impo-
tent. Potentiated Hsp104 variants suppress neurodegeneration
in aC. elegans PDmodel. Thus, we provide a promising example
of engineered disaggregases rescuing neurodegeneration in
a metazoan nervous system under conditions where the WT
disaggregase is ineffective. Our findings suggest that general
neuroprotection via activated protein disaggregases may be
possible for diverse neurodegenerative diseases.
We have identified the MD as a key region governing Hsp104
function. It is perplexing and unprecedented that missense mu-
tations to nearly any residue at specific and disparate positions
(e.g., A503, Y507) confer a therapeutic gain of function. Potenti-
ation stems from loss of amino acid identity rather than specific
mutation. Thus, Hsp104 activity is likely tightly constrained but
can be unleashed by subtle changes to side chains at specific
positions. These constraints are too tight for Hsp104WT to
counter TDP-43, FUS, and a-syn aggregation and toxicity under
the conditions employed in our experiments. Thus, we reveal a
surprising inimical deficit in existing disaggregase functionality.
We suggest that the MD functions as a capacitor braced to un-
leash Hsp104 activity. Missense mutations at specific positions
in MD helix 1, 2, or 3 or the small domain of NBD1 (immediately
C terminal to theMD) likely destabilize autoinhibitory interactions
that dampen Hsp104 activity or induce conformational changes
that mimic or aid in an allosteric activation step. Potentiating mu-
tations obviate any absolute requirement for Hsp70 and enhance
Hsp104 ATPase activity, substrate translocation speed, unfol-
dase activity, and amyloid disaggregase activity. Additionally,
Hsp104A503V hexamers display enhanced plasticity and are
more resistant to defective subunits than Hsp104WT. Thus,
enhanced variants possess a more robust disaggregase activity
that is desensitized to inhibition. Irrespective of the mechanism
of activation, we have established that seemingly minor struc-
tural modulation of a disaggregase can suppress a constellation
of otherwise intractable proteotoxicities in vivo. We are unaware
of any precedent for attaining such a wide-reaching set of gain of
therapeutic functions via such minor changes in primary
sequence, e.g., by removing a single methyl group (A503G) or
by adding a single methylene bridge (V426L).
Further engineering to develop enhanced variants that specif-
ically target single proteins (e.g., disaggregate FUS, but notCell 156, 170–182, January 16, 2014 ª2014 Elsevier Inc. 179
Figure 7. Potentiated Hsp104 Variants Disaggregate Preformed a-Syn, TDP-43, and FUS Fibrils More Efficaciously Than Hsp104WT
(A–C) a-syn fibrils were incubated without or with Hsp104WT, Hsp104A503V, Hsp104A503S, or Hsp104A503V-DPLF for 1 hr at 30C. Fiber disassembly was assessed
by ThT fluorescence (A), sedimentation analysis (B), or (C) EM (bar, 0.5 mm). (A and B) Values represent means ± SEM (n = 2).
(legend continued on next page)
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TDP-43) will prove valuable to minimize any off-target effects.
Hsp104 could be potentiated against any protein, which might
find key applications in purification of troublesome recombinant
proteins. Irrespective of the feasibility of introducing Hsp104 as a
therapeutic, our work suggests that protein aggregates are not
intractable and that general neuroprotection via altered proteo-
stasis is achievable. Ultimately, we envision introducing potenti-
ated Hsp104 variants in short transient bursts to restore natural
proteostasis. In this way, long-term expression of an exogenous
protein is avoided. Reactivation of disease-associated proteins
to their nonpathogenic states suggests that Hsp104 variants
and other agents that achieve this goal may be highly promising
for halting and reversing neurodegenerative disease. Nonethe-
less, caution is needed and many barriers must be breached
to translate Hsp104 variants into disruptive technologies and
potential therapeutics.
EXPERIMENTAL PROCEDURES
Yeast Strains and Media
Yeast were WTW303a or the isogenic W303aDhsp104 strain. Dire1 and Datg8
were in BY4741. Standard methods were used for transformation and spot-
ting. See the Extended Experimental Procedures for more information.
Library Construction and Screening
The pore loop variant library was constructed via QuikChange mutagenesis
(Agilent) and DNA shuffling to obtain randomly combined residues at positions
Y257 and Y662. The MD variant library was constructed using GeneMorph II
EZClone Domain Mutagenesis kit (Agilent) with modifications. Libraries were
transformed into yeast harboring pAG303GAL-TDP-43, pAG303GAL-FUS,
or pAG303GAL-a-syn. Yeast were grown overnight in raffinose-containing
media and plated on galactose-containing media for selection. Select colonies
were sequenced by colony PCR. Isolated Hsp104 variants were cloned inde-
pendently and transformed into yeast to ensure they suppressed toxicity. See
the Extended Experimental Procedures for more information.
Hsp104 Variant Toxicity and Thermotolerance
W303aDhsp104 yeast were transformed with the indicated 416GAL-Hsp104
plasmid. Cultures were grown in synthetic raffinose medium to A600nm = 2.0,
spotted onto SD-Ura or SGal-Ura, and incubated at 30C or 37C for 48–
72 hr. For thermotolerance, yeast were grown to saturation in synthetic raffi-
nose media and diluted to A600nm = 0.3 in galactose-containing media. After
4 hr at 30C, cells were heat shocked at 50C for 0–30 min, cooled for 2 min
on ice, serially diluted, and spotted on synthetic dropout media containing
galactose. Plates were incubated at 30C for 48–72 hr.
Sedimentation Analysis
Yeast were induced in galactose-containing medium for 5 hr (TDP-43 and
FUS) or 8 hr (a-syn). Cells were lysed, separated into soluble and insoluble
fractions by sedimentation, and processed for quantitative immunoblot. See
the Extended Experimental Procedures for more information.
Fluorescence Microscopy
After 5 hr induction at 30C (8 hr for a-syn strains), yeast cultures were pro-
cessed for fluorescence microscopy. For TDP-43, cells were fixed and stained
with 40,6-diamidino-2-phenylindole (DAPI) to visualize nuclei. For FUS, live
cells were used and nuclei were visualized with Hoechst dye. See the
Extended Experimental Procedures for more information.(D and E) TDP-43 aggregates were incubated with buffer, Hsp104WT, Hsp104A5
Aggregate dissolution assessed by turbidity. Values represent means ± SEM (n
(F and G) FUS aggregates were incubated with buffer, Hsp104WT, Hsp104A503V, or
dissolution assessed by turbidity (absorbance at 395 nm). Values represent meanAnalysis for Dopaminergic Neuron Death in C. elegans
Three distinct C. elegans stable lines were created for each Hsp104 variant.
Age synchronized worms were generated by allowing 50 transgenic adults
on a NGM plate to lay eggs for 3 hr. Adults were then removed (day 0). At
day 7 and 10 of analysis, 40 randomly selected transgenic worms were placed
in 3mM levamisol for paralysis and transferred to a 2%agarose pad on a glass
microscope slide. Worms have 8 dopaminergic neurons visible through Pdat-
1::gfp, which fade in an age-dependent manner due to a-syn accumulation.
Only the six anterior neurons of the worm were analyzed. Each worm was
scored ‘‘Wild Type’’ when there was a full complement of visible, anterior den-
dritic processes.Wormsmissing one ormore dendritic processeswere scored
‘‘Not Wild Type.’’ In total, three separate stable lines were analyzed. See the
Extended Experimental Procedures for more details.
Protein Purification
Proteins were purified as recombinant proteins in E. coli using standard tech-
niques (see Extended Experimental Procedures).
ATPase Activity
Hsp104 (0.042 mMhexamer) was incubated with ATP (1 mM) for 5 min at 25C.
ATPase activity was assessed by inorganic phosphate release using a mala-
chite green detection kit (Innova).
Luciferase Reactivation
Aggregated luciferase (50 nM) was incubated with Hsp104 (0.167 mM hex-
amer) with ATP (5.1mM) and an ATP regeneration system (ARS; 1mMcreatine
phosphate, 0.25 mM creatine kinase) plus or minus Hsc70 (0.167 mM) and Hdj2
(0.167 mM) for 90 min at 25C (DeSantis et al., 2012). In some reactions
(Figure 6C), Hsc70 concentration was 0.167 mM and Hdj2 concentration was
0.073mM. In other reactions, Hsc70 and Hdj2 were replaced with Ssa1
(0.167 mM) and Ydj1 (0.073 mM) or Ssa1 (0.167 mM), Ydj1 (0.073 mM), and
Sse1 (0.043 mM). Luciferase activity was assessed by luminescence.
Mutant doping experiments were as described previously (DeSantis et al.,
2012). The Hsp104A503V variants Hsp104A503V-DWA (K218T:A503V:K620T),
Hsp104A503V-DPLA (Y257A:A503V:Y662A), Hsp104A503V-DWB (E285Q:A503V:
E687Q), and Hsp104A503V-DPLA-DWB (Y257A:E285Q:A503V:Y662A:E687Q)
were mixed with Hsp104A503V in varying ratios to give a total concentration
of 0.5 mM Hsp104 hexamer. Hsc70 and Hdj2 were omitted for these experi-
ments. Random subunit mixing was confirmed by FRET. See the Extended
Experimental Procedures for more information.
RepA1-70-GFP Unfolding
RepA1-70-GFP unfolding was as described previously (Doyle et al., 2007).
FITC-Casein Degradation and Binding
FITC-casein (0.1–50 mM) was incubated at 25C with HAP or HAPA503V (1 mM
hexamer) and ClpP (21 mMmonomer) plus ATP (5 mM) and ARS. Degradation
of FITC-casein was monitored by fluorescence (excitation 490 nm, emission
520 nm). To calculate initial rate, a linear fit of the first 2.5 min of the reaction
was constructed and the slope was calculated. To assess binding, FITC-
casein (6 nM) was incubated with increasing concentrations (0–5 mM) of
Hsp104WT or Hsp104A503V with 2 mM ATPgS for 10 min at 25C. Fluorescence
polarization was measured (excitation 470 nm, emission 520 nm).
a-Syn Fibril Disaggregation
a-Syn (80 mM) was assembled into fibrils via incubation in 40 mMHEPES-KOH
(pH 7.4), 150 mM KCl, 20 mMMgCl2, 1 mM dithiothreitol for 48 hr at 37
C with
agitation. a-Syn fibrils (0.5 mM monomer) were incubated without or with
Hsp104WT, Hsp104A503V, Hsp104A503S, or Hsp104A503V-DPLF (0.5 or 5 mM)
plus ATP (10 mM) and ARS (20 mM creatine phosphate and 0.5 mM creatine03V, or Hsp104A503S plus or minus Ssa1, Ydj1, and Sse1 for 1 hr at 30C. (D)
= 3). (E) Aggregate dissolution assessed by EM. Scale bar, 0.5 mm.
Hsp104A503S plus or minus Ssa1, Ydj1, and Sse1 for 1 hr at 30C. (F) Aggregate
s ± SEM (n = 3). (G) Aggregate dissolution assessed by EM. Scale bar, 0.5 mm.
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kinase) for 1 hr at 30C. Disaggregation was assessed by Thioflavin-T (ThT)
fluorescence, sedimentation analysis, and EM (Lo Bianco et al., 2008).
TDP-43 and FUS Disaggregation
To generate TDP-43 and FUS aggregates, GST-TEV-TDP-43 (6 mM) or GST-
TEV-FUS (6 mM) was incubated with TEV protease in 50 mM Tris-HCl
(pH 7.4), 50 mM KCl, 5 mM MgCl2, 0.2 M trehalose, and 20 mM glutathione.
FUS was aggregated for 90 min at 25C without agitation, by which time all
the FUS had aggregated (Sun et al., 2011). TDP-43 was aggregated for 4 hr
at 25C with agitation, by which time all the TDP-43 had aggregated (Johnson
et al., 2009). TDP-43 or FUS aggregates (3 mM monomer) were incubated for
1 hr at 30Cwith Hsp104WT, Hsp104A503V, or Hsp104A503S (1 mM) plus orminus
Ssa1 (1 mM), Ydj1 (0.44 mM), and Sse1 (0.26 mM) plus ATP (10 mM) and ARS
(20 mM creatine phosphate and 0.5 mM creatine kinase). Disaggregation
was assessed via turbidity (absorbance at 395 nm) and EM (Johnson et al.,
2009; Sun et al., 2011).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
five figures and can be found with this article online at http://dx.doi.org/10.
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